Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUS PRIME: Optune GIO, MLA, and Pembrolizumab in Recurrent Glioblastoma
NCT06558214Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Dec 2024
- Primary completion
- Oct 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in glioblastoma (GBM), astrocytoma, sponsored by University of Florida. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT06558214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558214.